XTL Biopharmaceuticals Ltd.
XTLBHealthcare|Biotechnology|IL
$1.55
-0.16 (-9.36%)
Cash / Share
$0.02
About
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. Originally established in 1993 as Xenograft Technologies Ltd., the company rebranded to XTL Biopharmaceuticals Ltd. in July 1995. It operates from its headquarters in Ramat Gan, Israel.
Stock Price
-61.3%(1Y)
1M
-22.1%
3M
-47.3%
6M
-39.0%
YTD
-33.2%
1Y
-58.9%
3Y
-54.4%
5Y
-90.0%
Pipeline Summary
4 total trials2
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
Unknown: 2Withdrawn: 1Terminated: 1
Key Facts
Market Cap$1.5M
Employees0
CEONoam Band
IPO DateSep 1, 2005
Beta0.47
52-Week Range$1.55 – $5.64
Avg Volume10,174
ExchangeNASDAQ
Websitextlbio.com
Ownership
Float97.5%
Shares Outstanding9.5M
Recent Insider Trades
Hillel Fain OsnatOTHER
Mar 18, 20261,000,000 shares @ $0.01
Segal NivOTHER
Mar 18, 20260 shares
EDELMAN JOSEPHSELL
Nov 18, 200824,681,360 shares @ $0.14
EDELMAN JOSEPHSELL
Nov 18, 20082,696,450 shares @ $0.15
EDELMAN JOSEPHSELL
Nov 19, 20089,600,000 shares @ $0.15
Peers
Recent News
Burning Rock Biotech (NASDAQ:BNR) and XTL Biopharmaceuticals (NASDAQ:XTLB) Critical Analysis
Oct 13, 2026 · defenseworld.net
XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) Short Interest Update
Oct 3, 2026 · defenseworld.net
DBV Technologies (NASDAQ:DBVT) versus XTL Biopharmaceuticals (NASDAQ:XTLB) Financial Analysis
Sep 25, 2026 · defenseworld.net
Data last updated: Nov 9, 2026, 04:41 AM